Upfront allogeneic stem cell transplantation after reduced-intensity/nonmyeloablative conditioning for patients with myelodysplastic syndrome: A study by the société française de greffe de moelle et de thérapie cellulaire

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 9, 2014, Pages 1349-1355

  Damaj, Gandhi ^a   Mohty, Mohammad ^b   Robin, Marie ^c   Michallet, Mauricette ^d   Chevallier, Patrice ^e   Beguin, Yves ^f   Nguyen, Stephanie ^b   Bories, Pierre ^g   Blaise, Didier ^h   Maillard, Natacha ⁱ   Rubio, Marie Therese ^b   Fegueux, Nathalie ^j   Cornillon, Jerome ^k   Clavert, Aline ^l   Huynh, Anne ^m   Adès, Lionel ⁿ   Thiébaut Bertrand, Anne ^o   Hermine, Olivier ^p   Vigouroux, Stephane ^q   Fenaux, Pierre ⁿ   Duhamel, Alain ^r   Yakoub Agha, Ibrahim ^s   more..

^a CAEN UNIVERSITY HOSPITAL   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d CENTRE HOSPITALIER LYON SUD   (France)

^e NANTES UNIVERSITY HOSPITAL   (France)

^f UNIVERSITY OF LIÈGE   (Belgium)

^g UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^h INSTITUT PAOLI CALMETTES   (France)

ⁱ POITIERS UNIVERSITY HOSPITAL   (France)

^j MONTPELLIER UNIVERSITY HOSPITAL   (France)

^k RENNES UNIVERSITY HOSPITAL   (France)

^l ANGERS UNIVERSITY HOSPITAL   (France)

^m CHU PURPAN   (France)

ⁿ UNIVERSITÉ PARIS 13   (France)

^o GRENOBLE UNIVERSITY HOSPITAL   (France)

^p HÔPITAL NECKER ENFANTS MALADES   (France)

^q BORDEAUX UNIVERSITY HOSPITAL   (France)

^r Faculté de Médecine Pôle Recherché   (France)

^s LILLE UNIVERSITY HOSPITAL   (France)

more..

Author keywords

Azacitidine; Best supportive care; MDS; Transplantation

Indexed keywords

AZACITIDINE; ANTINEOPLASTIC ANTIMETABOLITE;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; FEMALE; FRANCE; HUMAN; INCIDENCE; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MORTALITY; MYELODYSPLASTIC SYNDROME; NONMYELOABLATIVE CONDITIONING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RECURRENCE FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; RELAPSE; TREATMENT OUTCOME; ALLOTRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROCEDURES; YOUNG ADULT;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84905514043     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.05.010     Document Type: Article

References (35)

1. Martino R., Valcarcel D., Brunet S., et al. Comparable non-relapse mortality and survival after HLA-identical sibling blood stem cell transplantation with reduced or conventional-intensity preparative regimens for high-risk myelodysplasia or acute myeloid leukemia in first remission. Bone Marrow Transplant 2008, 41:33-38.
2. de Witte T., Suciu S., Verhoef G., et al. Intensive chemotherapy followedby allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood 2001, 98:2326-2331.
3. Oran B., Giralt S., Saliba R., et al. Allogeneic hematopoietic stem celltransplantation for the treatment of high-risk acute myelogenousleukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. Biol Blood Marrow Transplant 2007, 13:454-462.
4. Yakoub-Agha I., de La Salmoniere P., Ribaud P., et al. Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients-report of the French society of bone marrow transplantation. JClin Oncol 2000, 18:963-971.
5. Warlick E.D., Cioc A., Defor T., et al. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden. Biol Blood Marrow Transplant 2009, 15:30-38.
6. Runde V., de Witte T., Arnold R., et al. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1998, 21:255-261.
7. Nakai K., Kanda Y., Fukuhara S., et al. Value of chemotherapy beforeallogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome. Leukemia 2005, 19:396-401.
8. Alessandrino E.P., Della Porta M.G., Pascutto C., et al. Should cytoreductive treatment be performed before transplantation in patients with high-risk myelodysplastic syndrome?. JClin Oncol 2013, 31:2761-2762.
9. De Witte T., Zwaan F., Hermans J., et al. Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG). Br J Haematol 1990, 74:151-155.
10. Damaj G., Duhamel A., Robin M., et al. Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: astudy by the Societe Francaise de Greffe de Moelle et de Therapie-Cellulaire and the Groupe-Francophone des Myelodysplasies. JClin Oncol 2013, 31:104-110.
11. Gerds A.T., Gooley T.A., Estey E.H., et al. Pretransplantation therapy withazacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS. Biol Blood Marrow Transplant 2012, 18:1211-1218.
12. Cogle C.R., Imanirad I., Wiggins L.E., et al. Hypomethylating agent inductiontherapy followed by hematopoietic cell transplantation is feasible in patients with myelodysplastic syndromes. Clin Adv Hematol Oncol 2010, 8:40-46.
13. Field T., Perkins J., Huang Y., et al. 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2010, 45:255-260.
14. Bacigalupo A., Ballen K., Rizzo D., et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009, 15:1628-1633.
15. Yakoub-Agha I., Mesnil F., Kuentz M., et al. Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. JClin Oncol 2006, 24:5695-5702.
16. Bennett J.M., Catovsky D., Daniel M.T., et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976, 33:451-458.
17. Swerdlow S.H., et al. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, International Agency for Research on Cancer, Lyon, France.
18. Greenberg P., Cox C., LeBeau M.M., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088.
19. Cheson B.D., Greenberg P.L., Bennett J.M., et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006, 108:419-425.
20. Kalbfleisch J.D. The statistical analysis of failure time data 2002, John Wiley & Sons, New York.
21. D'Agostino R.B. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998, 17:2265-2281.
22. Horwitz M.E. Reduced intensity versus myeloablative allogeneic stem cell transplantation for the treatment of acute myeloid leukemia, myelodysplastic syndrome and acute lymphoid leukemia. Curr Opin Oncol 2011, 23:197-202.
23. Baron F., Storb R. Current roles for allogeneic hematopoietic cell transplantation following nonmyeloablative or reduced-intensity conditioning. Clin Adv Hematol Oncol 2005, 3:799-819.
24. Buchholz S., Dammann E., Stadler M., et al. Cytoreductive treatment with clofarabine/ara-C combined with reduced-intensity conditioning and allogeneic stem cell transplantation in patients with high-risk, relapsed, or refractory acute myeloid leukemia and advanced myelodysplastic syndrome. Eur J Haematol 2011, 88:52-60.
25. de Witte T., Brand R., van Biezen A., et al. Allogeneic stem cell transplantation for patients with refractory anaemia with matched related and unrelated donors: delay of the transplant is associated with inferior survival. Br J Haematol 2009, 146:627-636.
26. Lim Z., Brand R., Martino R., et al. Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. JClin Oncol 2010, 28:405-411.
27. Bejar R., Stevenson K., Abdel-Wahab O., et al. Clinical effect of point mutations in myelodysplastic syndromes. NEngl J Med 2011, 364:2496-2506.
28. Itzykson R., Thepot S., Eclache V., et al. Prognostic significance of monosomal karyotype in higher risk myelodysplastic syndrome treated with azacitidine. Leukemia 2011, 25:1207-1209.
29. Husseinzadeh H., Evans E., Yoshida K., et al. Whole exome sequencing to predict response to hypomethylating agents in MDS. Blood 2012, 120;abstract 1698.
30. Itzykson R., Kosmider O., Cluzeau T., et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia 2011, 25:1147-1152.
31. Thudium K.E., Ghoshal S., Fetterly G.J., et al. Synergism between clofarabine and decitabine through p53R2: a pharmacodynamic drug-drug interaction modeling. Leuk Res 2012, 36:1410-1416.
32. Ades L., Itzykson R., Fenaux P. Treatment of advanced myelodysplastic syndrome with demethylating agents: azacitidine. Semin Hematol 2012, 49:323-329.
33. Cutler C.S., Lee S.J., Greenberg P., et al. Adecision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 2004, 104:579-585.
34. Cutler C. Allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndrome. Hematol Am Soc Hematol Educ Progr 2010, 2010:325-329.
35. Costantini B., Kordasti S., Kulasekararaj A.G., et al. The effects of 5-azacytidine on the function and number of regulatory T-cells and T-effectors in myelodysplastic syndrome. Haematologica 2013, 98:1196-1205.